Detection  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
investigation  ||| S:14 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
invasive  ||| S:31 E:40 ||| JJ
mould  ||| S:40 E:46 ||| JJ
disease  ||| S:46 E:54 ||| NN
A  ||| S:54 E:56 ||| DT
comprehensive  ||| S:56 E:70 ||| JJ
review  ||| S:70 E:77 ||| NN
of  ||| S:77 E:80 ||| IN
diagnostic  ||| S:80 E:91 ||| JJ
techniques  ||| S:91 E:102 ||| NNS
for  ||| S:102 E:106 ||| IN
opportunistic  ||| S:106 E:120 ||| JJ
systemic  ||| S:120 E:129 ||| NNS
mycoses  ||| S:129 E:137 ||| VBP
focused  ||| S:137 E:145 ||| VBN
on  ||| S:145 E:148 ||| IN
invasive  ||| S:148 E:157 ||| JJ
mould  ||| S:157 E:163 ||| JJ
disease  ||| S:163 E:171 ||| NN
in  ||| S:171 E:174 ||| IN
immunocompromised  ||| S:174 E:192 ||| JJ
patients  ||| S:192 E:201 ||| NNS
is  ||| S:201 E:204 ||| VBZ
presented ||| S:204 E:213 ||| VBN
.  ||| S:213 E:215 ||| .
We  ||| S:215 E:218 ||| PRP
first  ||| S:218 E:224 ||| RB
analysed  ||| S:224 E:233 ||| JJ
conventional  ||| S:233 E:246 ||| JJ
diagnostic  ||| S:246 E:257 ||| JJ
methods ||| S:257 E:264 ||| NNS
,  ||| S:264 E:266 ||| ,
such  ||| S:266 E:271 ||| JJ
as  ||| S:271 E:274 ||| IN
microscopy  ||| S:274 E:285 ||| JJ
examination ||| S:285 E:296 ||| NN
,  ||| S:296 E:298 ||| ,
culture  ||| S:298 E:306 ||| NN
and  ||| S:306 E:310 ||| CC
radiology ||| S:310 E:319 ||| NN
,  ||| S:319 E:321 ||| ,
underlining  ||| S:321 E:333 ||| VBG
their  ||| S:333 E:339 ||| PRP$
limitations ||| S:339 E:350 ||| NNS
,  ||| S:350 E:352 ||| ,
which  ||| S:352 E:358 ||| WDT
have  ||| S:358 E:363 ||| VBP
led  ||| S:363 E:367 ||| VBN
to  ||| S:367 E:370 ||| TO
the  ||| S:370 E:374 ||| DT
development  ||| S:374 E:386 ||| NN
of  ||| S:386 E:389 ||| IN
alternative  ||| S:389 E:401 ||| JJ
methods ||| S:401 E:408 ||| NNS
,  ||| S:408 E:410 ||| ,
such  ||| S:410 E:415 ||| JJ
as  ||| S:415 E:418 ||| IN
the  ||| S:418 E:422 ||| DT
detection  ||| S:422 E:432 ||| NN
of  ||| S:432 E:435 ||| IN
fungal  ||| S:435 E:442 ||| JJ
components ||| S:442 E:452 ||| NNS
.  ||| S:452 E:454 ||| .
Among  ||| S:454 E:460 ||| IN
these  ||| S:460 E:466 ||| DT
we  ||| S:466 E:469 ||| PRP
highlight  ||| S:469 E:479 ||| VB
fungal  ||| S:479 E:486 ||| JJ
antigen  ||| S:486 E:494 ||| NN
and  ||| S:494 E:498 ||| CC
DNA  ||| S:498 E:502 ||| NNP
quantification ||| S:502 E:516 ||| NN
,  ||| S:516 E:518 ||| ,
which  ||| S:518 E:524 ||| WDT
make  ||| S:524 E:529 ||| VBP
it  ||| S:529 E:532 ||| PRP
possible  ||| S:532 E:541 ||| JJ
to  ||| S:541 E:544 ||| TO
detect  ||| S:544 E:551 ||| VB
infections  ||| S:551 E:562 ||| JJ
early  ||| S:562 E:568 ||| JJ
and  ||| S:568 E:572 ||| CC
start  ||| S:572 E:578 ||| VB
appropriate  ||| S:578 E:590 ||| JJ
treatment ||| S:590 E:599 ||| NN
.  ||| S:599 E:601 ||| .
We  ||| S:601 E:604 ||| PRP
also  ||| S:604 E:609 ||| RB
briefly  ||| S:609 E:617 ||| RB
review  ||| S:617 E:624 ||| VB
the  ||| S:624 E:628 ||| DT
methods  ||| S:628 E:636 ||| NNS
for  ||| S:636 E:640 ||| IN
carrying  ||| S:640 E:649 ||| VBG
out  ||| S:649 E:653 ||| RP
susceptibility  ||| S:653 E:668 ||| JJ
tests  ||| S:668 E:674 ||| NNS
for  ||| S:674 E:678 ||| IN
antifungal  ||| S:678 E:689 ||| JJ
drugs ||| S:689 E:694 ||| NNS
,  ||| S:694 E:696 ||| ,
including  ||| S:696 E:706 ||| VBG
reference  ||| S:706 E:716 ||| NN
procedures ||| S:716 E:726 ||| NNS
,  ||| S:726 E:728 ||| ,
commercial  ||| S:728 E:739 ||| JJ
techniques  ||| S:739 E:750 ||| NNS
and  ||| S:750 E:754 ||| CC
their  ||| S:754 E:760 ||| PRP$
indications ||| S:760 E:771 ||| NNS
.  ||| S:771 E:773 ||| .
Furthermore ||| S:773 E:784 ||| RB
,  ||| S:784 E:786 ||| ,
we  ||| S:786 E:789 ||| PRP
analyse  ||| S:789 E:797 ||| VBD
the  ||| S:797 E:801 ||| DT
recommendations  ||| S:801 E:817 ||| NNS
for  ||| S:817 E:821 ||| IN
therapeutic  ||| S:821 E:833 ||| JJ
drug  ||| S:833 E:838 ||| NN
monitoring  ||| S:838 E:849 ||| NN
of  ||| S:849 E:852 ||| IN
antifungal  ||| S:852 E:863 ||| JJ
agents  ||| S:863 E:870 ||| NNS
in  ||| S:870 E:873 ||| IN
body  ||| S:873 E:878 ||| NN
fluids ||| S:878 E:884 ||| NNS
.  ||| S:884 E:886 ||| .
